Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12888049 | 0.77 | ALDH1A1 (0.38) | ALDH1A1TSHRTDP1 | |
| SCHEMBL18500728 | 0.73 | ALDH1A1 (0.35) | ALDH1A1TSHRTDP1 | |
| SCHEMBL62598 | 0.71 | — | — | |
| SCHEMBL9095605 | 0.70 | — | — | |
| SCHEMBL22641704 | 0.69 | TSHR (0.45) | ALDH1A1TSHRTDP1 | |
| SCHEMBL3146943 | 0.69 | — | — | |
| SCHEMBL5932196 | 0.67 | — | — | |
| SCHEMBL13174761 | 0.67 | — | — | |
| SCHEMBL15135119 | 0.67 | TSHR (0.43) | ALDH1A1TSHRTDP1 | |
| SCHEMBL6178791 | 0.67 | TSHR (0.43) | ALDH1A1TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362246-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2017-12-21 | — | — | US | disclosed |
| EP-2245009-B1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF 5-BIPHENYL-4-YL-2-METHYLPENTANOIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2016-08-10 | — | — | EP | disclosed |
| US-9403766-B2 | Intermediates for producing NEP inhibitors or prodrugs thereof | NOVARTIS AG (CH) | 2016-08-02 | — | — | US | disclosed |
| US-20160060217-A1 | Processes | HOOK DAVID (CH) | 2016-03-03 | — | — | US | disclosed |
| US-9227934-B2 | Processes for producing NEP inhibitors or prodrugs thereof | NOVARTIS AG (CH) | 2016-01-05 | — | — | US | disclosed |
| US-20150246881-A1 | Processes | NOVARTIS AG (CH) | 2015-09-03 | — | — | US | disclosed |
| US-9061973-B2 | Processes for producing NEP inhibitors or prodrugs thereof | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2015-06-23 | — | — | US | disclosed |
| US-9061973-B2 | Processes for producing NEP inhibitors or prodrugs thereof | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2015-06-23 | — | — | US | disclosed |
| US-20140243546-A1 | Processes | NOVARTIS AG (CH) | 2014-08-28 | — | — | US | disclosed |
| US-20140243546-A1 | Processes | NOVARTIS AG (CH) | 2014-08-28 | — | — | US | disclosed |
| US-8716481-B2 | Process for the preparation of 6-substituted-1-(2H)-isoquinolinones | SANOFI (FR) | 2014-05-06 | — | — | US | disclosed |
| US-8580974-B2 | Processes | NOVARTIS AG (CH) | 2013-11-12 | — | — | US | disclosed |
| US-20110046397-A1 | NEW PROCESSES | NOVARTIS PHARMACEUTICALS CORPORATION | 2011-02-24 | — | — | US | disclosed |
| US-20110021779-A1 | PROCESS FOR THE PREPARATION OF 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES | SANOFI-AVENTIS (FR) | 2011-01-27 | — | — | US | disclosed |
| EP-2245009-A2 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF 5-BIPHENYL-4-YL-2-METHYLPENTANOIC ACID DERIVATIVES | Novartis AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| EP-2240441-A1 | PROCESS FOR THE PREPARATION OF 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES | Sanofi-Aventis (FR) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009090251-A2 | NEW PROCESSES | NOVARTIS AG (CH) | 2009-07-23 | — | — | WO | disclosed |
| WO-2009080335-A1 | PROCESS FOR THE PREPARATION OF 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES | SANOFI-AVENTIS (FR) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362246-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | ALDH1A1 4117/4885TSHR 3200/4885TDP1 284/4885 |
| US-20110021779-A1 | PROCESS FOR THE PREPARATION OF 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES | CYP1B1, CYP1A1, NQO1 | ALDH1A1 90/4885TSHR 4350/4885TDP1 1506/4885 |
| US-20160060217-A1 | Processes | MME, NAT1, AGTR1 | ALDH1A1 134/4885TSHR 3125/4885TDP1 1039/4885 |
| US-20110046397-A1 | NEW PROCESSES | MME, REN, AGTR1 | ALDH1A1 197/4885TSHR 3271/4885TDP1 1615/4885 |
| US-20140243546-A1 | Processes | MME, NAT1, AGTR1 | ALDH1A1 134/4885TSHR 3125/4885TDP1 1039/4885 |
| US-20150246881-A1 | Processes | MME, NAT1, AGTR1 | ALDH1A1 134/4885TSHR 3125/4885TDP1 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.